{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T22:06:53Z","timestamp":1764022013963,"version":"3.45.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T00:00:00Z","timestamp":1760832000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T00:00:00Z","timestamp":1760832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s10147-025-02900-4","type":"journal-article","created":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T11:03:41Z","timestamp":1760871821000},"page":"2618-2625","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of FOLFOX for Japanese patients with advanced biliary tract cancer as second-line or later chemotherapy (JON2107-B study)"],"prefix":"10.1007","volume":"30","author":[{"given":"Takeshi","family":"Terashima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6560-7503","authenticated-orcid":false,"given":"Chigusa","family":"Morizane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiko","family":"Chida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Todaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kumiko","family":"Umemoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujiro","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junji","family":"Furuse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Nagano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,19]]},"reference":[{"key":"2900_CR1","doi-asserted-by":"publisher","first-page":"426","DOI":"10.2188\/jea.JE20200416","volume":"31","author":"K Katanoda","year":"2021","unstructured":"Katanoda K, Hori M, Saito E et al (2021) Updated trends in cancer in Japan: incidence in 1985\u20132015 and mortality in 1958\u20132018 \u2013 a sign of decrease in cancer incidence. J Epidemiol 31:426\u2013450","journal-title":"J Epidemiol"},{"key":"2900_CR2","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1002\/cncr.29692","volume":"122","author":"NF Esnaola","year":"2016","unstructured":"Esnaola NF, Meyer JE, Karachristos A et al (2016) Evaluation and management of intrahepatic and extrahepatic cholangiocarcinoma. Cancer 122:1349\u20131369","journal-title":"Cancer"},{"key":"2900_CR3","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s00534-007-1280-z","volume":"15","author":"J Furuse","year":"2008","unstructured":"Furuse J, Takada T, Miyazaki M et al (2008) Guidelines for chemotherapy of biliary tract and ampullary carcinomas. J Hepatobiliary Pancreat Surg 15:55\u201362","journal-title":"J Hepatobiliary Pancreat Surg"},{"key":"2900_CR4","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362:1273\u20131281","journal-title":"N Engl J Med"},{"key":"2900_CR5","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1093\/annonc\/mdz402","volume":"30","author":"C Morizane","year":"2019","unstructured":"Morizane C, Okusaka T, Mizusawa J et al (2019) Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced\/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial. Ann Oncol 30:1950\u20131958","journal-title":"Ann Oncol"},{"key":"2900_CR6","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1002\/jhbp.1219","volume":"30","author":"T Ioka","year":"2023","unstructured":"Ioka T, Kanai M, Kobayashi S et al (2023) Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401-MITSUBA). J Hepatobiliary Pancreat Sci 30:102\u2013110","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2900_CR7","doi-asserted-by":"publisher","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","volume":"1","author":"DY Oh","year":"2022","unstructured":"Oh DY, Ruth HA, Qin S et al (2022) Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid 1:EVIDoa2200015","journal-title":"NEJM Evid"},{"key":"2900_CR8","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C et al (2023) Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 401:1853\u20131865","journal-title":"Lancet"},{"key":"2900_CR9","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.2217\/fon-2021-1302","volume":"18","author":"ZS Khankhel","year":"2022","unstructured":"Khankhel ZS, Goring S, Bobiak S et al (2022) Second-line treatments in advanced biliary tract cancer: systematic literature review of efficacy, effectiveness and safety. Future Oncol 18:2321\u20132338","journal-title":"Future Oncol"},{"key":"2900_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2022.102010","volume":"46","author":"C Nuezillet","year":"2022","unstructured":"Nuezillet C, Malka D, Li\u00e8vre A et al (2022) Correlation between efficacy endpoints in patients with advanced biliary tract cancer treated by systemic second-line therapies: analysis of aggregated data from a systematic literature review. Clin Res Hepatol Gastroenterol 46:102010","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"2900_CR11","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","volume":"22","author":"A Lamarca","year":"2021","unstructured":"Lamarca A, Palmer DH, Wasan HS et al (2021) Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3 open-label, randomized, controlled trial. Lancet Oncol 22:690\u2013701","journal-title":"Lancet Oncol"},{"key":"2900_CR12","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","volume":"34","author":"A Vogel","year":"2023","unstructured":"Vogel A, Bridgewater J, Edeline J et al (2023) Biliary tract cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 34:127\u2013140","journal-title":"Ann Oncol"},{"key":"2900_CR13","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s00280-007-0673-7","volume":"62","author":"J Furuse","year":"2008","unstructured":"Furuse J, Okusaka T, Boku N et al (2008) S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study. Cancer Chemother Pharmacol 62:849\u2013855","journal-title":"Cancer Chemother Pharmacol"},{"key":"2900_CR14","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1002\/jhbp.1418","volume":"31","author":"M Ueno","year":"2024","unstructured":"Ueno M, Shirakawa S, Tokumaru J et al (2024) Real-world evidence of systemic treatment practices for biliary tract cancer in Japan: results of a database study. J Hepatobiliary Pancreat Sci 31:468\u2013480","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2900_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10147-019-01485-z","volume":"25","author":"Y Hashiguchi","year":"2020","unstructured":"Hashiguchi Y, Muro K, Saito Y et al (2020) Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol 25:1\u201342","journal-title":"Int J Clin Oncol"},{"key":"2900_CR16","doi-asserted-by":"publisher","first-page":"8301","DOI":"10.2147\/OTT.S184665","volume":"11","author":"H Osumi","year":"2018","unstructured":"Osumi H, Takahari D, Chin K et al (2018) Modified FOLFOX6 as a first-line treatment for patients with advanced gastric cancer with massive ascites or inadequate oral intake. Onco Targets Ther 11:8301\u20138307","journal-title":"Onco Targets Ther"},{"key":"2900_CR17","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1080\/14737140.2021.1982699","volume":"21","author":"M Persano","year":"2021","unstructured":"Persano M, Puzzoni M, Ziranu P et al (2021) Molecular-driven treatment for biliary tract cancer: the promising turning point. Expert Rev Anticancer Ther 21:1253\u20131264","journal-title":"Expert Rev Anticancer Ther"},{"key":"2900_CR18","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2206834","volume":"388","author":"L Goyal","year":"2023","unstructured":"Goyal L, Meric-Bernstam F, Hollebecque A et al (2023) Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma. N Engl J Med 388:228\u2013239","journal-title":"N Engl J Med"},{"key":"2900_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103488","volume":"9","author":"A Vogel","year":"2024","unstructured":"Vogel A, Sahai V, Hollebecque A et al (2024) An open-label studyh of pemigatinib in cholangiocarcinoma: final results from FIGHT-202. ESMO Open 9:103488","journal-title":"ESMO Open"},{"key":"2900_CR20","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/jhbp.870","volume":"28","author":"M Nagino","year":"2021","unstructured":"Nagino M, Hirano S, Yoshitomi H et al (2021) Clinical practice guidelines for the management of biliary tract cancers 2019: the 3rd English edition. J Hepatobiliary Pancreat Sci 28:26\u201354","journal-title":"J Hepatobiliary Pancreat Sci"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02900-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02900-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02900-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T22:02:26Z","timestamp":1764021746000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02900-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,19]]},"references-count":20,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2900"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02900-4","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"type":"print","value":"1341-9625"},{"type":"electronic","value":"1437-7772"}],"subject":[],"published":{"date-parts":[[2025,10,19]]},"assertion":[{"value":"15 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Takeshi Terashima and Junji Furuse received lecture fees from Astrazeneca K.K., and Makoto Ueno received research fundings from Taiho Pharmaceutical Co., Ltd., AstraZeneca, K.K,\u00a0MSD K.K,\u00a0Nihon Servier\u00a0Co., Ltd.,\u00a0Ono Pharmaceutical\u00a0Co., Ltd.,\u00a0Incyte Biosciences Japan GK,\u00a0Chugai Pharmaceutical\u00a0Co., Ltd.,\u00a0Boehringer Ingelheim\u00a0GmbH,\u00a0Eisai Co., Ltd.,\u00a0Novartis Pharma K.K, Astellas Pharma Inc.,\u00a0J-pharma\u00a0Co., Ltd.,\u00a0DFP (Delta Fly Pharma), Inc., Novocure GmbH, and Chiome Bioscience Inc..","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}